Given the role of integrin/FAK/YAP/TAZ in NSCLC development, we conjectured that suppression of integrin/FAK/YAP/TAZ signals by Y15 could restrain tumor growth and improve the outcome of chemotherapy. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.